Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Q2

<< Previous

Bullboard Posts

Next >>

Post by Trogarzonon Jul 10, 2023 11:17am

211 Views

Post# 35533591

Q2

So wednesday is Q2... they reiterated twice already the 90m annual guidance and mentioned the strong second half of the year forecast. We will see about that on the 12th. I want to know your thoughts. Mine is that they will miss as usual and cut forecast and talk the walk and walk the talk as usual. So more of the same.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec